{"entity":{"id":"transgene","kind":"company","name":"Transgene","aka":[],"tldr":"Transgene uses modified viruses to make cancer immunotherapies. Its lead product is a personalised vaccine built from each patient's tumour mutations, given after surgery to stop head and neck cancer coming back.","summary":"Transgene (Euronext Paris: TNG) designs virus-based immunotherapies for cancer. Its myvac platform produces individualised neoantigen vaccines on a modified vaccinia Ankara vector, with neoantigens selected by NEC's AI. Lead candidate TG4050 encodes up to 30 patient-specific neoantigens and is in a randomised phase 1/2 trial in resected HPV-negative head and neck squamous cell carcinoma. In September 2026 Transgene and NEC reported 100 percent three-year disease-free survival in all 16 TG4050-treated phase 1 patients versus three relapses among 16 controls (median follow-up 41 months), published in Nature Communications; phase 2 results are expected around the end of 2027. TG4070 extends myvac into adjuvant non-small cell lung cancer (phase 1); oncolytic viruses BT-001 and TG6050 follow. In November 2025 the company raised about EUR 105 million, with Institut Mérieux (via TSGH) and the Dassault Group participating, extending financial visibility to early 2028.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.transgene.com/"},{"label":"Fundraising of about EUR 105 million (November 2025)","url":"https://www.transgene.com/wp-content/uploads/Transgene_PR_Results_EN.pdf"},{"label":"TG4050 three-year disease-free survival and Nature Communications publication","url":"https://www.transgene.com/wp-content/uploads/20260902_TG4050_NatCom_EN.pdf"}],"tags":[],"related":[],"cancers":["head-and-neck","nsclc"],"sections":["immunotherapy"],"technologies":["neoantigen-mrna-vaccine","oncolytic-virus"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct03260023","nct04183166"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Founding year not sourced."],"hq":"Strasbourg","country":"FR","companyType":"biotech","website":"https://www.transgene.com/","ticker":"TNG.PA","stage":"public","investors":[],"funding":[{"round":"Crossover","year":2025,"source":"https://www.transgene.com/wp-content/uploads/Transgene_PR_Results_EN.pdf","note":"Public follow-on fundraising of about EUR 105 million (private placement plus PrimaryBid retail offering at EUR 1.02 per share), plus a EUR 39.3 million reserved capital increase for TSGH by set-off of advances"}]},"route":"/companies/transgene/","neighbours":{"cancer":[{"id":"head-and-neck","kind":"cancer","name":"Head and neck squamous cell carcinoma","route":"/cancers/head-and-neck/"},{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"}],"section":[{"id":"immunotherapy","kind":"section","name":"Immunotherapy","route":"/fronts/immunotherapy/"}],"technology":[{"id":"oncolytic-virus","kind":"technology","name":"Oncolytic viruses","route":"/technologies/oncolytic-virus/"},{"id":"neoantigen-mrna-vaccine","kind":"technology","name":"Personalised neoantigen (mRNA) vaccines","route":"/technologies/neoantigen-mrna-vaccine/"}],"trial":[{"id":"nct04183166","kind":"trial","name":"A Clinical Trial Evaluating TG4050 in Head and Neck Cancer","route":"/trials/nct04183166/"},{"id":"nct03260023","kind":"trial","name":"Phase Ib/II of TG4001 and Avelumab in HPV16 Positive R/M Cancers","route":"/trials/nct03260023/"}]}}